Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Anta Sports, conducted share buybacks on September 25, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent [1]. Company Buyback Details - Tencent Holdings (00700) repurchased 844,000 shares for a total of 550 million, with a year-to-date total of 63.29 million shares, representing 0.689% of its total share capital [2]. - Anta Sports (02020) repurchased 1.065 million shares for 99.82 million, with a year-to-date total of 7.31 million shares, accounting for 0.260% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 8.1 million shares for 32.97 million, with a year-to-date total of 92.44 million shares, representing 0.080% of its total share capital [2]. - China Hongqiao Group (01378) repurchased 1 million shares for 24.87 million, with a year-to-date total of 153 million shares, accounting for 1.630% of its total share capital [2]. - CIMC (02039) repurchased 3.04 million shares for 23.37 million, with a year-to-date total of 24.78 million shares, representing 0.800% of its total share capital [2]. - Hang Seng Bank (00011) repurchased 200,000 shares for 23.13 million, with a year-to-date total of 7.93 million shares, accounting for 0.421% of its total share capital [2]. - MGM China (02282) repurchased 1 million shares for 15.75 million, with a year-to-date total of 2.58 million shares, representing 0.680% of its total share capital [2]. - Haier Smart Home (06690) repurchased 600,000 shares for 15.17 million, with a year-to-date total of 1.65 million shares, accounting for 0.058% of its total share capital [2]. - Other companies such as Coolpad Group (02369) and Xinyi International (00732) also engaged in buybacks, with Coolpad repurchasing 1.088 million shares for 1.38 million, representing 7.166% of its total share capital [2].

Core Viewpoint - The company, 加科思药业, demonstrates strong confidence in its long-term development through significant share buybacks and insider purchases, contrasting with the trend of executive sell-offs in the Hong Kong pharmaceutical sector [1][4]. Group 1: Executive Actions - 加科思药业's Chairman and CEO, Dr. Wang Yinxiang, along with associates, invested nearly HKD 100 million to purchase over 11.05 million shares, signaling confidence in the company's future [1]. - The company has initiated a share buyback plan of HKD 100 million, with approximately HKD 26.7 million executed so far, indicating ongoing commitment to shareholder value [1]. Group 2: Clinical Value - 加科思药业 focuses on KRAS and iADC as its primary research directions, with KRAS mutations present in about 25% of cancer patients [2]. - The company's KRAS G12C inhibitor, Glecirasib, received approval for second-line treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC) and has been successfully launched in China, triggering a milestone payment of RMB 50 million from a partner [2]. - The pan-KRAS inhibitor, JAB-23E73, has shown multiple confirmed partial response cases in ongoing Phase I clinical trials in China and the U.S., with complete data expected in the first half of 2026 [2]. Group 3: Commercial Potential - 加科思 is advancing a second-generation product, EGFR-KRAS G12D tADC, which aims to deliver KRAS G12D inhibitors effectively, potentially becoming a major product in colorectal cancer by submitting an IND application in the second half of 2026 [3]. - The company is also developing HER2-STING iADC (JAB-BX467) to address the limitations of PD-1 monotherapy in "cold tumors," with plans to submit an IND application in the second half of 2026 [3]. Group 4: Value Assessment - 加科思's focus on KRAS and iADC positions it well in a market where 25% of cancer patients have KRAS mutations and nearly 70% are cold tumors, establishing a clear potential for clinical and commercial success [4]. - The market has not fully reflected the pipeline value and long-term growth potential of 加科思, with a comparison to Revolution Medicine's market cap of USD 8 billion versus 加科思's HKD 7 billion [4]. - The combination of significant insider purchases and the ongoing buyback plan sends a strong signal of management's confidence in the company's long-term prospects [4].

Core Viewpoint - The company, 加科思药业, demonstrates strong confidence in its long-term development through significant share buybacks and insider purchases, despite a broader trend of executive sell-offs in the Hong Kong pharmaceutical sector [1][4]. Group 1: Executive Actions - The chairman and CEO, Dr. Wang Yinxiang, along with associates, invested nearly HKD 100 million to purchase over 11.05 million shares of the company [1]. - The company has initiated a share buyback plan of HKD 100 million, with approximately HKD 26.7 million executed so far, and plans to continue this over the next year [1]. Group 2: Clinical Value - 加科思 focuses on KRAS and iADC as its primary research directions, with KRAS being a critical mutation pathway in cancer, affecting about 25% of cancer patients [2]. - The company's KRAS G12C inhibitor, Glecirasib, received approval for second-line treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC) and has been successfully launched in China, triggering a milestone payment of RMB 50 million from a partner [2]. - The pan-KRAS inhibitor, JAB-23E73, has shown multiple confirmed partial response cases in ongoing Phase I clinical trials in China and the U.S., with complete data expected in the first half of 2026 [2]. Group 3: Commercial Potential - 加科思 is advancing a second-generation product, EGFR-KRAS G12D tADC, which aims for precise delivery in colorectal cancer, with an IND application expected in the second half of 2026 [3]. - The company is also developing HER2-STING iADC (JAB-BX467) to address the limitations of PD-1 monotherapy in "cold tumors," with plans to submit an IND application in the second half of 2026 [3]. Group 4: Value Assessment - With 25% of cancer patients carrying KRAS mutations and nearly 70% being cold tumors, 加科思's focus on KRAS and iADC provides a clear long-term growth potential [4]. - The market has not fully reflected the pipeline value and long-term growth potential of 加科思, as evidenced by its market capitalization of HKD 7 billion compared to Revolution Medicine's USD 8 billion [4]. - The significant insider purchases and ongoing buyback plan signal management's confidence in the company's long-term prospects, suggesting a potential market revaluation as clinical data continues to validate its pipeline [4].

Group 1 - The company, 加科思-B (01167.HK), announced a share buyback on September 25, spending 1.5 million HKD to repurchase 163,000 shares [1] - On September 24, the company also conducted a buyback, spending 500,000 HKD to repurchase 52,000 shares [1]

Core Viewpoint - The company demonstrates strong confidence in its future development prospects, as evidenced by significant share purchases by concerted action members and a share buyback plan [1][2] Group 1: Share Purchases - Concerted action members have collectively purchased 11.05865 million shares at a total cost of approximately 96.34 million HKD since July 16, 2025 [1] - As of the announcement date, these members hold about 200.2 million shares, representing 25.28% of the company's total issued shares [1] - The members express confidence in the company's overall development prospects, growth potential, and long-term investment value [1] Group 2: Share Buyback Plan - The board has approved a share buyback plan not exceeding 100 million HKD, believing that the current share price does not reflect the company's actual value [1] - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of 2.67 million HKD [1] - The company will continue to monitor market conditions and may exercise shareholder authorization for further share repurchases [1] Group 3: Business Operations and Product Pipeline - The board believes that the company's current business operations are in good condition, with encouraging progress in the development of core product pipelines, including but not limited to Pan-KRAS inhibitors [2] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [2]

Core Viewpoint - The company, 加科思-B (01167), has received notification from its concerted action members expressing strong confidence in the company's future development prospects, leading to significant share purchases and a share buyback program [1] Group 1: Share Purchases - From July 16, 2025, to the date of the announcement, concerted action members have collectively purchased 11,058,650 shares at a total cost of approximately HKD 96.34 million [1] - As of the announcement date, these members hold a total of 200 million shares, representing about 25.28% of the company's total issued shares [1] Group 2: Share Buyback - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of HKD 2.67 million [1] - The company plans to continue monitoring market conditions and may exercise shareholder authorization for further share repurchases based on market circumstances [1] Group 3: Business Outlook - The company reports that its current business operations are performing well, with encouraging progress in the research and development of its core product pipeline, including the Pan-KRAS inhibitor [1] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [1]

Core Viewpoint - The company has received strong confidence from its concerted action members regarding its future development prospects, leading to significant share purchases and a share buyback program [1] Group 1: Share Purchases - From July 16, 2025, to the date of the announcement, concerted action members have collectively purchased 11,058,650 shares at a total cost of approximately HKD 96.34 million [1] - As of the announcement date, concerted action members hold a total of 200 million shares, representing about 25.28% of the company's total issued shares [1] Group 2: Management Confidence - The concerted action members expressed strong confidence in the company's overall development prospects, growth potential, and long-term investment value of its shares [1] - The company does not rule out the possibility of further share purchases by concerted action members, subject to applicable laws and regulations [1] Group 3: Share Buyback Program - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of HKD 2.67 million [1] - The company will continue to monitor market conditions and may exercise its shareholder authorization to repurchase shares based on market circumstances [1] Group 4: Business Operations - The company's current business operations are reported to be in good condition, with encouraging progress in the research and development of its core product pipeline, including the Pan-KRAS inhibitor [1] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. — 1 — 二、股份回購情況 茲提述本公司日期為2025年7月16日之公告，內容有關董事會批准不超過100百萬港幣 於市場上購回本公司股份（「股份回購計劃」）。董事會認為，目前的股份價格並未反 映公司的實際價值。自2025年7月15日起直至本公告日期，本公司已合計購回326,400 股股份，累計支付對價為2.67百萬港幣。本公司將繼續關注市場情況，並可能根據市 場狀況進一步行使股東授權回購股份。 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 自願公告 一致行動人士持有本公司股份之變動及 本公司於市場上購回股份進展 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者 ...

加科思-B(01167)发布公告，于2025年9月25日斥资149.96万港元回购16.35万股。 ...

智通财经APP讯，加科思-B(01167)发布公告，于2025年9月25日斥资149.96万港元回购16.35万股。 ...